Moberg Pharma strengthens leadership ahead of European launches
Moberg Pharma AB is making changes to its management team and organization in preparation for upcoming product launches in Europe. Two new members will join the executive team.
Moberg Pharma AB has announced changes to its management team and organization as part of its preparations for upcoming product launches in Europe. The company is strengthening its structure alongside ongoing launch preparations and regulatory processes in new markets.
Helena Jansson joins as Chief Business Officer and Deputy CEO, and Vaidrius Navikas will take on the role of Chief Medical Officer. Concurrently, Christina Erixon will step down from the management team.
Development of Mitalce, the company's new dermatology drug for skin cancer, has progressed. Moberg Pharma anticipates its marketing authorization application will be reviewed by the European Medicines Agency (EMA) by the end of 2026, paving the way for launch preparations in multiple European countries.
Moberg Pharma is a pharmaceutical company focused on dermatology products. The company is pursuing international growth and is focused on launching new products and expanding its market presence.